Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, discusses updated safety data from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in PD-L1–positive TNBC.

Sara Tolaney, MD, MPH, outlines emerging treatments and trials in the first-line setting for triple-negative breast cancer

Sara Tolaney, MD, MPH, discusses the clinical implications of sacituzumab govitecan in the first-line treatment of advanced triple-negative breast cancer.

Sara M. Tolaney, MD, MPH, discusses the design and potential significance of the ongoing ELEGANT trial of elacestrant in ER-positive early breast cancer.

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

Sara M. Tolaney, MD, MPH, discusses the potential role of Sac-TMT with/without pembrolizumab in HR+, HER2– breast cancer.

Sara Tolaney, MD, MPH, presents primary results from the Phase 3 ASCENT-04/KEYNOTE-D19 study showing that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival with manageable safety versus chemotherapy plus pembrolizumab in previously untreated PD-L1–positive advanced triple-negative breast cancer.

Sara Tolaney, MD, MPH, presents results from the phase 3 DESTINY-Breast09 study showing that trastuzumab deruxtecan plus pertuzumab improved progression-free survival vs taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer.

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.